JP6904909B2 - 非晶質の金属有機構造体 - Google Patents

非晶質の金属有機構造体 Download PDF

Info

Publication number
JP6904909B2
JP6904909B2 JP2017566712A JP2017566712A JP6904909B2 JP 6904909 B2 JP6904909 B2 JP 6904909B2 JP 2017566712 A JP2017566712 A JP 2017566712A JP 2017566712 A JP2017566712 A JP 2017566712A JP 6904909 B2 JP6904909 B2 JP 6904909B2
Authority
JP
Japan
Prior art keywords
metal
organic
amorphous metal
amorphous
organic framework
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017566712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522860A5 (https=
JP2018522860A (ja
Inventor
クラウディア・オレジャーナ−タヴラ
ナイジェル・スレーター
デイヴィッド・ファイレン−ヒメネス
ミシェル・テプレンスキー
エマ・バクスター
トーマス・ベネット
アンソニー・チータム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2018522860A publication Critical patent/JP2018522860A/ja
Publication of JP2018522860A5 publication Critical patent/JP2018522860A5/ja
Application granted granted Critical
Publication of JP6904909B2 publication Critical patent/JP6904909B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/94—Bismuth compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017566712A 2015-06-24 2016-06-24 非晶質の金属有機構造体 Expired - Fee Related JP6904909B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1511125.5A GB201511125D0 (en) 2015-06-24 2015-06-24 Amorhous metal-organic frameworks
GB1511125.5 2015-06-24
PCT/EP2016/064746 WO2016207397A1 (en) 2015-06-24 2016-06-24 Amorphous metal-organic frameworks

Publications (3)

Publication Number Publication Date
JP2018522860A JP2018522860A (ja) 2018-08-16
JP2018522860A5 JP2018522860A5 (https=) 2019-07-25
JP6904909B2 true JP6904909B2 (ja) 2021-07-21

Family

ID=53784456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566712A Expired - Fee Related JP6904909B2 (ja) 2015-06-24 2016-06-24 非晶質の金属有機構造体

Country Status (6)

Country Link
US (1) US11083795B2 (https=)
EP (1) EP3313856A1 (https=)
JP (1) JP6904909B2 (https=)
CN (1) CN107771084A (https=)
GB (1) GB201511125D0 (https=)
WO (1) WO2016207397A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736967B2 (en) 2016-01-05 2020-08-11 Panaceanano, Inc. Method of preparing cyclodextrin complexes
US10583147B2 (en) * 2016-03-24 2020-03-10 Panaceanano, Inc. Compositions containing cyclodextrin-based metal organic frameworks
WO2018044874A1 (en) * 2016-08-29 2018-03-08 Cornell University Metal organic frameworks and methods of making and using same
GB201717975D0 (en) * 2017-10-31 2017-12-13 Cambridge Entpr Ltd Metal organic framework-based compositions and uses thereof
CN108456241A (zh) * 2018-01-17 2018-08-28 南开大学 多孔框架材料用于生物制品的储运和制备
WO2019173571A1 (en) * 2018-03-09 2019-09-12 Northwestern University Insulin-loaded metal-organic frameworks
KR102125431B1 (ko) * 2018-10-12 2020-06-23 한국과학기술연구원 크기가 조절된 UiO-66의 제조방법 및 이에 따라 제조된 활성이 향상된 화학작용제 가수분해 촉매
US20210386055A1 (en) * 2018-10-30 2021-12-16 Unm Rainforest Innovations Metal-organic Framework-Assisted Cryopreservation of Red Blood-Cells
WO2021035010A1 (en) * 2019-08-20 2021-02-25 Shengqian Ma Corrole-based frameworks and methods of use thereof
GB201917388D0 (en) * 2019-11-28 2020-01-15 Cambridge Entpr Ltd Novel linker compounds
KR102253318B1 (ko) * 2020-06-02 2021-05-18 (주)위바이오트리 금속 상 변환 화합물 및 이의 제조 방법
CN112500581B (zh) * 2020-12-08 2022-01-28 广西民族师范学院 一种基于1,3,5-三(甲氧基羧基)苯构筑的镍金属配位聚合物及其合成方法
EP4011365A1 (en) 2020-12-09 2022-06-15 Cambridge Enterprise, Ltd. Mof nanoparticles
CN113398956B (zh) * 2021-06-17 2023-08-04 西安石油大学 一种可见光响应的BiOI光催化剂及其制备方法和应用
CN113791058B (zh) * 2021-09-15 2022-09-23 南京大学 一种利用lmof组成的传感器阵列检测抗生素的方法
CN114657600B (zh) * 2022-04-25 2023-05-19 江西师范大学 一种3D微米花复合材料Fe-CoP@C及其制备方法和应用
US20250351820A1 (en) * 2022-06-06 2025-11-20 Kansas State University Research Foundation Supramolecular porous organic frameworks for storage and delivery of volatile guests
CN115785468A (zh) * 2022-11-21 2023-03-14 苏州大学 一种用于富集细胞外囊泡的zif-8-dspe材料及其制备方法和应用
CN116584480B (zh) * 2023-04-26 2025-05-23 南京大学 金属有机框架纳米农药控释剂的制备方法及其应用
CN119371711B (zh) * 2024-10-30 2025-06-24 江南大学 一种非晶共轭配位聚合物气凝胶材料及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024789B2 (ja) * 1976-09-03 1985-06-14 小野薬品工業株式会社 ５−フルオロウラシル誘導体化合物

Also Published As

Publication number Publication date
EP3313856A1 (en) 2018-05-02
WO2016207397A1 (en) 2016-12-29
US20180147284A1 (en) 2018-05-31
GB201511125D0 (en) 2015-08-05
US11083795B2 (en) 2021-08-10
CN107771084A (zh) 2018-03-06
JP2018522860A (ja) 2018-08-16

Similar Documents

Publication Publication Date Title
JP6904909B2 (ja) 非晶質の金属有機構造体
Orellana-Tavra et al. Amorphous metal–organic frameworks for drug delivery
Ahlberg et al. PVP-coated, negatively charged silver nanoparticles: A multi-center study of their physicochemical characteristics, cell culture and in vivo experiments
EP2260048B1 (fr) Solide hybride cristallin poreux pour l'adsorption et la liberation de gaz a interet biologique
Yokel et al. The yin: an adverse health perspective of nanoceria: uptake, distribution, accumulation, and mechanisms of its toxicity
Kittler et al. The influence of proteins on the dispersability and cell-biological activity of silver nanoparticles
Chen et al. Stimuli-responsive functionalized mesoporous silica nanoparticles for drug release in response to various biological stimuli
Lawson et al. Optimizing ibuprofen concentration for rapid pharmacokinetics on biocompatible zinc-based MOF-74 and UTSA-74
Pandit et al. Iron oxide nanoparticle encapsulated; folic acid tethered dual metal organic framework-based nanocomposite for MRI and selective targeting of folate receptor expressing breast cancer cells
Far et al. Co-delivery of doxorubicin/sorafenib by DNA-decorated green ZIF-67-based nanocarriers for chemotherapy and hepatocellular carcinoma treatment
Zhang et al. Tannic acid-assisted synthesis of biodegradable and antibacterial mesoporous organosilica nanoparticles decorated with nanosilver
Chowdhury The applications of metal-organic-frameworks in controlled release of drugs
Liang et al. A stable biocompatible porous coordination cage promotes in vivo liver tumor inhibition
Tabatabaeian et al. N-doped carbon nanodots@ UiO-66-NH2 as novel nanoparticles for releasing of the bioactive drug, rosmarinic acid and fluorescence imaging
Rahimi et al. Synthesis, characterization, and toxicity assessments of Silymarin-loaded Ni-Fe Metal-organic frameworks: Evidence from in vitro and in vivo evaluations
Parsaei et al. Effects of fluorinated functionalization of linker on quercetin encapsulation, release and HeLa cell cytotoxicity of Cu‐based MOFs as smart pH‐stimuli nanocarriers
Saif et al. Potential of CME@ ZIF-8 MOF nanoformulation: smart delivery of silymarin for enhanced performance and mechanism in albino rats
Kulkarni et al. Engineered transferrin-conjugated PEGylated multifunctional MOF-74 as precision nanotheranostics for triple-negative breast cancer
Hashemi et al. Novel Metal–Organic Framework Nanoparticle for Letrozole Delivery: A New Advancement in Breast Cancer Treatment
CN101945671B (zh) 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统
Salleh et al. Gelatin-coated zeolite y for controlled release of anticancer drug (zerumbone)
Truter et al. Assessment of the antitumour activity of targeted immunospecific albumin microspheres loaded with cisplatin and 5‐fluorouracil: toxicity against a rodent ovarian carcinoma in vitro
Bai et al. Carrier-free doxorubicin/rhein supramolecular co-assembly for cancer therapy
RU2493857C1 (ru) Способ получения биологически активной наножидкости на основе наночастиц оксида железа (ii, iii) и производного 3-гидроксипиридина
KR20220000850A (ko) 비타민 b1의 보호 및 전달을 위한 장용성 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210624

R150 Certificate of patent or registration of utility model

Ref document number: 6904909

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees